Evommune (EVMN) EBIT Margin (2025)
Evommune's (EVMN) quarterly EBIT Margin came in at 133.28% in Q3 2025, up 73.4% on a QoQ basis from 501.07% in Q1 2025.
Evommune (EVMN) EBIT Margin (2025) Analysis & Trends
Evommune (EVMN) has 1 years of EBIT Margin data on file, last reported at 133.28% in Q3 2025.
- On a quarterly basis, EBIT Margin changed N/A year-over-year to 133.28% in Q3 2025; TTM through Mar 2026 was 631.0%, a N/A change from a year earlier, with the FY2025 full-year figure at 623.62%, up 37656.0% from the prior year.
- EBIT Margin for Q3 2025 stood at 133.28%, up from 501.07% in the prior quarter.
- Over the last five years, EBIT Margin for EVMN reached as high as 133.28% in Q3 2025 and fell as low as 501.07% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Evommune | 381.48 Mn | 170.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -133.28% |
| Mar 31, 2025 | -501.07% |